Erythromycin is the standard antibiotic used for treatment of infection with Ureaplasma spp. during pregnancy; however, maternally administered erythromycin may be ineffective at eliminating intra-amniotic ureaplasma infections. We examined whether erythromycin would eradicate intra-amniotic ureaplasma infections in pregnant sheep. At Gestational Day (GD) 50 (term, GD 150), pregnant ewes received intra-amniotic injections of erythromycin-sensitive Ureaplasma parvum serovar 3 (n ¼ 16) or 10B medium (n ¼ 16). At GD 100, amniocentesis was performed; five fetal losses (ureaplasma group, n ¼ 4; 10B group, n ¼ 1) had occurred by this time. Remaining ewes were allocated into treatment subgroups: medium only (n ¼ 7), medium and erythromycin (n ¼ 8), ureaplasma only (Up; n ¼ 6), or ureaplasma and erythromycin (Up/E; n ¼ 6). Erythromycin was administered intramuscularly (500 mg) every 8 h for 4 days (GDs 100-104). Amniotic fluid samples were collected at GD 105. At GD 125, preterm fetuses were surgically delivered, and specimens were collected for culture and histology. Erythromycin was quantified in amniotic fluid by liquid chromatographymass spectrometry. Ureaplasmas were isolated from the amniotic fluid, chorioamnion, and fetal lung of animals from the Up and Up/E groups, however, the numbers of U. parvum recovered were not different between these groups. Inflammation in the chorioamnion, cord, and fetal lung was increased in ureaplasma-exposed animals compared to controls but was not different between the Up and Up/E groups. Erythromycin was detected in amniotic fluid samples, although concentrations were low (,10-76 ng/ml). This study demonstrates that maternally administered erythromycin does not eradicate chronic, intra-amniotic ureaplasma infections or improve fetal outcomes in an ovine model, potentially because of the poor placental passage of erythromycin. microbiology, placenta, placental transport, pregnancy
INTRODUCTION
In 2008, 12.3% of babies in the United States were born preterm (,37 wk of gestation). Despite the recent 3% decline, the U.S. preterm birth rate rose by more than 20% between 1990 and 2006 [1] . In the developed world, preterm birth is the leading cause of neonatal death [2] and accounts for 75% of perinatal mortality and more than half of long-term infant and childhood morbidity [3] . Approximately 30% of all preterm births are associated with an infectious etiology [4] , and the most common pathogens associated with preterm birth are the human ureaplasmas [5] .
The human ureaplasmas (Ureaplasma parvum and Ureaplasma urealyticum) are the most frequently isolated microorganisms from the amniotic fluid (AF) [6] [7] [8] and placentae [9, 10] of pregnant women and have been associated with adverse pregnancy outcomes, including chorioamnionitis, preterm rupture of membranes (PROM), and preterm birth. Ureaplasmas are able to infect fetal tissues in utero and are associated with neonatal diseases such as bronchopulmonary dysplasia, pneumonia, and meningitis [11] [12] [13] . Experiments in rhesus macaques have demonstrated that ureaplasmas can cause chorioamnionitis and induce preterm labor and fetal lung injury as a sole pathogen [14] .
Treatment of intra-amniotic ureaplasma infections with antimicrobials is predicted to improve pregnancy outcomes and reduce neonatal morbidity and mortality rates [15, 16] . In clinical practice, the standard antibiotics used to treat Ureaplasma spp. are the macrolides, which include erythromycin, roxithromycin, and azithromycin [17] . Of these, erythromycin is the most frequently used to treat ureaplasma infections during pregnancy, because its use was associated with a range of benefits for the neonate after administration to pregnant women with preterm, prelabor rupture of membranes (PPROM) in the ORACLE I trial. In that randomized trial, the use of erythromycin was associated with prolongation of pregnancy, fewer major cerebral abnormalities, fewer positive blood cultures, reduction in neonatal surfactant treatment, and decreases in oxygen dependence at 28 days or more of age [18] .
Despite evidence of benefit to the newborn, the literature contains little agreement regarding the effectiveness of erythromycin for the eradication of intra-amniotic infections. There are reports of maternally administered erythromycin eliminating intra-amniotic ureaplasma infections during pregnancy [19] ; however, when erythromycin was administered to women colonized with ureaplasmas in the lower genital tract [20] or who presented with PPROM [21] , this treatment did not prevent preterm delivery or eradicate intra-amniotic infection.
Additionally, results of a 7-yr follow-up of the ORACLE II trial found that children whose mothers had been in spontaneous preterm labor with intact membranes and received either erythromycin or amoxicillin-clavulanate had increased rates of cerebral palsy [22] , suggesting the use of antibiotics during pregnancy may have some inherent risks. Despite this conflicting evidence, erythromycin still is routinely administered to women with PPROM as standard treatment.
The present study aimed to investigate the efficacy of erythromycin in eradicating chronic, intra-amniotic ureaplasma infection in an established large-animal model [23] [24] [25] . We studied the in vivo effects of erythromycin by comparing 1) ureaplasma colonization of AF and fetal tissues, 2) fetal inflammation, and 3) pregnancy outcomes between animals receiving either erythromycin treatment or no treatment.
MATERIALS AND METHODS
The present experiments were approved by the Animal Ethics Committees of the University of Western Australia, Cincinnati Children's Hospital Medical Centre, and Queensland University of Technology.
The low-passage, erythromycin-sensitive U. parvum serovar 3 (isolate 442S) used for the present was originally isolated from the semen of an infertile man attending the Wesley IVF Service (Brisbane, QLD, Australia). This patient gave informed consent for the isolate to be used for research. Ureaplasmas for injection were prepared as previously described [24] and diluted to 2 3 10 4 colony-forming units (CFUs) in PBS before injection.
At Gestational Day (GD) 50 (term, GD 150), 32 date-mated Merino ewes bearing single fetuses received intra-amniotic injections guided by ultrasound imaging. Briefly, before injection, 2 ml of AF were aspirated to confirm the injection site by electrolyte analysis (Rapidlab 865; Bayer Diagnostics). The same needle was used to inject 2 ml of either U. parvum (2 3 10 4 CFUs, n ¼ 16) or 10B broth (medium control, n ¼ 16) [26] .
At GD 100, ewes were examined by ultrasound, and five were no longer pregnant (ureaplasma group, n ¼ 4; 10B medium group, n ¼ 1). The remaining pregnant ewes were allocated into one of four treatment subgroups: 1) medium only (M; n ¼ 7), 2) medium and erythromycin (M/E; n ¼ 8), 3) ureaplasma inoculum only (Up; n ¼ 6), or 4) ureaplasma inoculum and erythromycin (Up/ E; n ¼ 6). The ewes that received erythromycin were injected intra-muscularly with 500 mg of erythromycin (Abbot Australasia) three times daily for 4 days (GDs 100-104), resulting in a dosage of 30 mg kg À1 day À1 . This regimen was selected because it is similar to erythromycin treatment given to pregnant women, which is variable but often 10-20 mg kg À1 day
À1
) [19] , and is an appropriate dose for administration to sheep [27] .
Specimen Collection
The AF samples were collected by amniocentesis at GD 100 (just before commencement of erythromycin treatment), at GD 105 (24 h after completion of erythromycin treatment), and at GD 125 (just before surgical delivery of the preterm fetus).
At GD 125, ewes were anesthetized by an intramuscular injection of 12 mg/ kg of ketamine and 0.12 mg/kg of metatomidine followed by a subdural injection of 2% lignocaine (60 mg, 3 ml), and then the uterus was incised through a maternal laparotomy. The fetal membranes were isolated, and AF was aspirated using a sterile needle and syringe. The fetus was delivered, and umbilical arterial blood was collected. The fetus was then killed by injection of a lethal dose of sodium pentobarbitone (100 mg/kg i.v.) and weighed. Duplicate samples of chorioamnion and umbilical cord (cord) were aseptically collected and either snap-frozen in liquid nitrogen or fixed in 10% neutral buffered formalin.
The lambs were exsanguinated, the chest opened, and a deflation pressurevolume curve performed after air inflation of the lungs to a pressure of 40 cm H 2 O. Pieces of the lower lobe of the right lung were snap-frozen, and the upper lobe of the right lung was fixed by airway instillation of 10% neutral buffered formalin at a pressure of 30 cm H 2 O. Fetal cerebrospinal fluid (CSF) was collected aseptically by needle aspiration and snap-frozen for subsequent culture.
Complete blood counts (CBCs) were performed on heparinized umbilical arterial blood by a commercial laboratory (Vet Path).
Ureaplasma Culture and Quantification
The AF, chorioamnion, cord, fetal lung, and fetal CSF specimens from all animals were cultured for ureaplasmas to determine ureaplasma CFUs per milliliter of fluid or gram of tissue. Thawed chorioamnion, cord, and fetal lung (0.1 g) were initially homogenized in 1.5 ml of 10B broth using a mini beadbeater eight-cell disrupter (Daintree Scientific). All specimens were then inoculated into 10B broth, and nine 10-fold serial dilutions were performed as previously described [28] . For each specimen, six 5-ll drops from the 10-fold dilutions were subsequently inoculated onto A8 agar plates [29] , which were incubated in 5% CO 2 for 48-72 h. From the dilution containing countable colonies (;30-300 colonies/drop), ureaplasma colonies were counted from each of the six 5-ll drops using a stereomicroscope (Leica Microsystems). The average number of colonies per 5-ll drop was calculated, and total CFUs per milliliter of fluid or gram of tissue for each specimen was determined. To eliminate bias, the microbiologist who cultured and counted these colonies was blinded to the treatment groups of the specimens.
Specimens that were ureaplasma culture negative were tested for the presence of ureaplasmal DNA by PCR assay. DNA was extracted from the specimen using the QIAamp Mini Kit (Qiagen) as per the protocol provided by the manufacturer for DNA purification from blood or bodily fluids. PCR primers targeting the multiple-banded antigen gene (mba, UMS-125 5 0 -GTATTTGCAATCTTTATATGTTTTCG and UMA226 5 0 -CAGCTGATG TAAGTGCAGCATTAAATTC) [30] were used to detect and speciate noncultivable ureaplasmas within tissues. PCR assays were performed in a 50-ll reaction mixture containing 100 lM of dNTP mix (Roche Diagnostics), 13 PCR buffer (Tris-HCl, KCl, and (NH 4 ) 2 SO 4 ; pH 8.7; Invitrogen), 1.5 mM of MgCl 2 (Invitrogen), 0.5 lM of each primer (Sigma), 2.5 U of Platinum Taq Polymerase (Invitrogen), and sterile distilled water. PCR cycling, in a PTC-2000 Thermal Cycler (Global Medical Instrumentation), involved initial denaturation at 948C for 15 min; followed by 35 cycles of denaturation at 948C for 1 min, primer annealing at 568C for 1 min, and extension at 728C for 1 min; and then a final extension step at 728C for 10 min. Positive PCR controls included DNA extracted from the ureaplasma inoculum (isolate 442S) and U. parvum serovar 3 reference strain (courtesy of H. Watson, University of Alabama, Birmingham, AL). Negative controls included master mix only and reaction mixtures with distilled water substituted for template. All PCR products were electrophoresed through a 2% agarose gel at 110 V for 60 min. Amplicons were visualized by ethidium bromide (10 lg/ml) staining and digitized using Grab-It Gel Dock (Ultraviolet Products Ltd.).
Quantification of Erythromycin in AF
The detection and quantification of erythromycin in AF samples collected at GD 105 and GD 125 from the M/E (four of eight animals) and Up/E (six of six animals) groups was performed using liquid chromatography-mass spectrometry (Metabolomics Australia). Samples from only four of eight animals from the M/E group were analyzed because of limited sample availability. The assay had a limit of detection of 10 ng/ml and an intra-assay variation of 2.8%, and it enabled accurate quantification of erythromycin levels within each AF sample, calculated from a unique mass fingerprint [31, 32] .
Histology and Inflammatory Cell Counts
Formalin-fixed samples of chorioamnion, cord, and fetal lung (right upper lobe) were embedded in paraffin and cut into sections (thickness, 5 lm) for staining with hematoxylin and eosin. All stained sections were examined (in a blinded fashion) to determine numbers of total white blood cells, monocytes, lymphocytes, and neutrophils present in 20 microscopic fields per slide at 31000 total magnification. Inflammatory cells were identified and distinguished visually based on cellular and nuclear morphology and cell size. Chorioamnion sections were also graded for the severity of histological chorioamnionitis. Scoring was based on a semiquantitative four-grade system developed within our laboratory, using a minimum score of 1 (representing minimal inflammatory cell infiltrate and no tissue fibrosis, necrosis, or abscesses) and a maximum score of 4 (heavy inflammatory cell infiltrate and severe fibrosis, necrosis, or abscesses).
Statistical Analysis
Data are presented as the mean 6 SEM. The culture data were log 10 -transformed to ensure normality of data, then analyzed by independent t-tests to compare CFUs between animal groups. The AF ureaplasma CFU/ml data were analyzed within each group across the three time points by two-way repeatedmeasures ANOVA. Inflammatory cell counts, CBC data, and fetal physiological data were analyzed by one-way ANOVA with a Tukey post hoc test. Lung compliance data were analyzed by a two-way repeated-measures ANOVA. Homogeneity of variances was confirmed for each test as appropriate; statistical significance was accepted at P , 0.05.
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RESULTS
Ureaplasma Culture and Quantification
At GD 100 (50 days after ureaplasma injection and before erythromycin treatment), 100% of AF samples collected from animals inoculated with ureaplasmas tested ureaplasma positive, with AF ureaplasma ranging from 2.0 3 10 5 to 1.76 3 10 8 CFU/ml (Fig. 1A) . Upon retesting of AF at GD 105 (24 h after completion of erythromycin treatment), all animals from the Up and Up/E groups remained ureaplasma culture positive, with no change in the numbers of U. parvum recovered. AF ureaplasma CFU/ml data were not different between Up and Up/E groups, either before or after erythromycin treatment (P . 0.05). All control animals tested negative for ureaplasmas by culture at these time points.
At GD 125 (the time of surgical delivery of the fetus), the AF of all animals that had been inoculated with ureaplasmas (100%) tested positive by culture for Ureaplasma spp. Ureaplasmas were also cultured from the chorioamnion of four of six (67%) animals from the Up group and four of six (67%) animals from the Up/E group, the umbilical cords from two of six (33%) animals from the Up group and one of six (17%) animals from the Up/E group, and the fetal lung tissue from five of six (83%) animals from the Up group and all of the Up/E group (100%) (Fig. 1B) . No ureaplasmas were cultured from any fetal CSF specimens, and no ureaplasmas were cultured from any specimens from noninfected control animals.
The AF ureaplasma CFU/ml data at GD 125d were not different between the Up and Up/E groups (P . 0.05). At GD 125, the value in the Up group appeared to have increased compared with GD 105 (Fig. 1A) ; however, this increase was not statistically significant (P . 0.05). This increase was not evident in the Up/E group, in which AF ureaplasma CFU/ml remained relatively unchanged throughout the tested time points. The number of recoverable ureaplasma CFUs was higher in the AF compared to the chorioamnion (Up, P ¼ 0.23; Up/E, P ¼ 0.41), cord (Up, P ¼ 0.23; Up/E, P ¼ 0.47), and fetal lung (Up, P ¼ 0.90; Up/E, P ¼ 0.14): however, these differences did not reach statistical significance.
From those specimens that tested negative for ureaplasmas by culture, DNA was extracted, and PCR was performed to detect ureaplasmal DNA. Of these specimens, four of four (100%) chorioamnion specimens, seven of nine (78%) cord specimens, and one of one (100%) fetal lung specimen gave positive PCR assay results. No ureaplasmas were detected in the fetal CSF specimens (0%, n ¼ 27) by the PCR assay.
Chorioamnionitis and Fetal Inflammation
Histological chorioamnionitis was evident in animals from the Up and Up/E groups when compared to controls, as demonstrated by an increase in inflammatory cells in the chorioamnion (Fig. 2A) . Counts of lymphocytes (P ¼ 0.012) and neutrophils (P ¼ 0.03), but not monocytes (P ¼ 0.167), were significantly higher in the Up/E group when compared to the M/E control group. No differences were found in inflammatory cell counts in the chorioamnion between the Up and Up/E groups (P . 0.05).
Histopathological grading of inflammation in chorioamnion tissues was consistent with the inflammatory cell count data: Animals from the control groups did not have evidence of chorioamnionitis; whereas animals from the Up and Up/E groups had scores indicating moderate to severe histological chorioamnionitis (Fig. 2B) . No differences in the severity of chorioamnionitis were found between the Up and Up/E groups. Representative sections demonstrating the grading of histological chorioamnionitis (grades 1-4) are shown in Figure 2C .
Inflammatory cell counts within cord tissue were significantly increased in the Up and Up/E groups compared to the respective control groups for monocytes (P ¼ 0.001), lymphocytes (P ¼ 0.001), and neutrophils (P ¼ 0.001) (Fig.  2D ). In addition, increased numbers of monocytes were found in fetal lung tissue in the Up and Up/E groups compared to controls (P ¼ 0.001). Lymphocyte numbers were significantly increased in the Up group compared to the M group only (P ¼ 0.041), but neutrophil numbers were not different between groups (P ¼ 0.119) (Fig. 2E) . In all tissues examined, no differences were found in inflammatory cell counts between the Up/E and Up groups.
Total white blood cell counts from fetal umbilical arterial blood were not different between animals in the Up and Up/E FIG. 1. A) Ureaplasma colonization within AF samples at GD 100 (100d), GD 105 (105d), and GD 125 (125d) was not different between the Up group and the Up/E group. B) At GD 125, ureaplasmas were isolated from the chorioamnion, cord, and fetal lung, however, no differences were found in CFUs per milliliter or per gram of tissue between the groups that received intra-amniotic ureaplasma injections. Bars represent the mean þ SEM.
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FIG. 2. Inflammation of fetal tissues.
A and B) Increased inflammatory cell counts (A) were observed in chorioamnion sections from animals inoculated with ureaplasmas compared to controls, and the histological chorioamnionitis score (B) was also increased in these animals. C) Representative hematoxylin and eosin-stained sections of chorioamnion displaying various stages of histological chorioamnionitis. Grades 1-4 are shown from left to right: grade 1 (uninfected control), minimal inflammatory cell infiltrate and no tissue fibrosis, necrosis, or abscesses; grade 2, mild inflammatory cell infiltrate (arrows) and mild tissue fibrosis, necrosis, or abscesses; grade 3, heavy inflammatory cell infiltrate and moderate tissue fibrosis, necrosis, or abscesses (arrows represent moderate levels of scar tissue formation and fibrosis); and grade 4, heavy inflammatory cell infiltrate and severe fibrosis, necrosis, or abscesses. Arrows represent severe fibrosis and disruption of normal tissue morphology. Bars ¼ 50 lm. D and E) Inflammatory cell counts were also increased in umbilical cord and fetal lung tissue sections in animals in the Up group and the Up/E group. Values are presented as the mean þ SEM. *P , 0.05 vs. M/E control group only, #P , 0.05 vs. the M control group only, **P , 0.05 vs. both M/E and M control groups.
TREATMENT OF INTRA-AMNIOTIC UREAPLASMA INFECTIONS groups compared to controls, except for lymphocytes, which were increased in the M/E control group compared to the Up group (P ¼ 0.02) ( Table 1) .
Fetal Growth and Well-Being
Fetal body weight at the time of preterm delivery was not different between Up and Up/E groups and controls (Table 1) . Similarly, intra-amniotic ureaplasma infection did not affect fetal lung weight relative to body weight (Table 1) or fetal umbilical arterial pH or partial pressure of oxygen at the time of delivery (Table 1) compared to control animals. Fetal lung compliance (as indicated by lung volume at 40 cm H 2 O) was increased in Up and Up/E groups compared to controls (Table  1) ; however, this increase was not statistically significant. Lung compliance was not different between Up and Up/E animal groups.
AF Erythromycin Quantification
Erythromycin was detected in 100% of AF samples from the M/E and Up/E groups collected at GD 105, and concentrations ranged from below detectable limits (,10 ng/ml) to 75.7 ng/ml (Fig. 3) . At GD 125, erythromycin levels were below detectable limits of the assay in 50% of animals from the M/ E group and 83% of animals from the Up/E group. No differences in mean AF erythromycin concentration were found between the M/E and the Up/E groups at GD 105 (P ¼ 0.42) and GD 125 (P ¼ 0.76). Erythromycin was not detected in any AF specimens collected from animals that did not receive erythromycin treatment (data not shown).
DISCUSSION
Treatment of pregnant women with erythromycin occurs routinely in clinical obstetrics. As a macrolide antibiotic, erythromycin has broad-spectrum activity and is appropriate for use in pregnancy (pregnancy category A) [33] . By inhibiting protein synthesis at the 50S ribosomal subunit [17] , erythromycin is, unlike other broad-spectrum beta-lactam antibiotics, potentially active against Ureaplasma spp., which lack a cell wall. Our data, however, clearly demonstrate that maternal erythromycin treatment, as administered in the present experiment, is ineffective at eliminating intra-amniotic ureaplasma infections or improving fetal outcomes in an ovine model.
Erythromycin treatment did not significantly reduce or eliminate ureaplasma colonization within the AF, chorioamnion, or fetal lung when compared to animals that did not receive antibiotic treatment. Remarkably, even at GD 105 (24 h after completion of antibiotic treatment), the number of recoverable ureaplasma CFUs within the AF remained unchanged in comparison to the number before erythromycin treatment (GD 100). Our data showed that AF ureaplasma CFU/ml at GD 125 was increased in the Up group but not in the Up/E group. This observation, although not statistically significant, is consistent with the bacteriostatic, rather than bacteriocidal, action of erythromycin, suggesting that after erythromycin was depleted, the ureaplasmas were able to again replicate. Collectively, these data indicate that the erythromycin had no significant effect on the short-term survival of ureaplasmas or their ability to cause long-term, chronic infections. We also found that erythromycin treatment did not reduce fetal inflammation of the chorioamnion or fetal lungs, nor did it have any effect on the severity of histological chorioamnionitis. Similarly, fetal outcomes (including fetal lung compliance) were not altered by the administration of erythromycin in this experiment.
Our findings are in agreement with data from human clinical studies. In a study of serial amniocenteses in which pregnant women with PPROM were treated using ampicillin and erythromycin and women with evidence of intra-amniotic infection were treated using ceftriaxone, clindamycin, and erythromycin [21] , maternal systemic antibiotic therapy rarely (3/18, 16.7%) eradicated intra-amniotic infection. Furthermore, 32% (9/28) of patients who did not have intra-amniotic infection/inflammation at admission subsequently developed intra-amniotic inflammation, despite antibiotic treatment. In another study [20] , women with lower-genital-tract ureaplasma colonization received either erythromycin treatment or placebo. Erythromycin treatment had no effect on infant birth weight, gestational age at delivery, frequency of PROM, or neonatal outcomes compared to women who received a placebo. Similarly, results of the ORACLE II randomized trial of women in preterm labor with intact membranes [34] and a Cochrane review of 15 trials [35] suggest that maternally administered antibiotics do not improve pregnancy outcomes. The literature indicates that these antibiotics have very little therapeutic and/or prophylactic benefit. To the best of our knowledge, ours is the first animal model to fully assess the effects of erythromycin on chronic, intra-amniotic ureaplasma infections, and it demonstrates the likely reason for the lack of efficacy in preventing adverse pregnancy outcomes. Conversely, some studies have reported successful eradication of human intra-amniotic infections and improved pregnancy outcomes after antibiotic treatment [19] . In an analysis of 2718 genetic amniocentesis specimens by Berg et al. [36] , 1.8% of AF specimens were found to be culture positive for genital mycoplasmas (including Ureaplasma spp. and Mycoplasma hominis). Based on these results, patients were either treated with oral erythromycin for 10 days (n ¼ 34) or not treated (n ¼ 9), and pregnancy outcomes were compared. Midtrimester pregnancy loss was significantly decreased in the treated group (11.4%) compared to the untreated group (44.4%); however, preterm delivery rates were not different between groups. Others have reported successful eradication of Ureaplasma spp. from the AF and prolongation of pregnancy after erythromycin treatment [15, 16, 37] . These reports should be interpreted cautiously, however, because they are either single case reports, involve different ureaplasma serovars and culture techniques, use different treatment protocols, or have large inequalities in sample sizes (evidenced by Berg et al. [36] ).
To date, the failure of erythromycin to eradicate intraamniotic infections is thought to result from poor placental passage [38] . After ex vivo perfusion of single placental cotyledons from women who delivered at term, the transplacental transfer of erythromycin was only 3.0% [38] . Our experiment shows that the transplacental passage of erythromycin in vivo is low and is the most likely determinant for the ineffectiveness of erythromycin treatment during pregnancy. Our study was not designed as a pharmacokinetic experiment, and as a result, our sample collection did not occur at the times that would have enabled us to determine the maximum concentration of erythromycin within the AF. In humans, erythromycin has a reported serum half-life of approximately 1.4 h [39] ; therefore, our measurements at GD 105 most likely represent the erythromycin concentration after several halflives have passed. However, the Merck Veterinary Manual reports that after an intramuscular injection of erythromycin, effective inhibitory concentrations are maintained for 12-24 h in sheep [40] . Another limitation of our experiment was that we did not collect serum samples for the quantification of erythromycin within maternal and fetal plasma. Furthermore, a potential contributor toward our findings may be the anatomy of the ovine placenta, which is synepitheliochorial [41, 42] , with six layers interposed between the maternal and fetal circulations [43] . In contrast, the human placenta is hemochorial [44] , with three layers separating the maternal and fetal circulations [43] . Because of these anatomical differences, the permeability of the ovine placenta is lower than that of humans [43, 45, 46] and, therefore, may provide a greater barrier against transfer of antimicrobial agents. Despite these differences, our study demonstrates that erythromycin can enter the AF after maternal administration to pregnant sheep; however, it appears to be present at concentrations most likely below the minimum inhibitory concentrations required to eradicate Ureaplasma spp. Further pharmacokinetic studies would be helpful to better define erythromycin levels in the fetal compartment.
Based on our data and the collective reports of others, we conclude that erythromycin has little therapeutic value for the improvement of fetal outcomes, because it does not eradicate or reduce intra-amniotic ureaplasma infection or reduce inflammation. Furthermore, potential risks are associated with administering erythromycin during pregnancy. A 7-yr followup of the ORACLE II trial found an increase in functional impairment and cerebral palsy in children who were exposed to erythromycin in utero [22] . One possible cause of this morbidity arises from the concept of incomplete treatment. Partial eradication of the intrauterine infection may diminish the provocation of preterm labor but not remove the infection from the fetus, thus allowing continuation of the pregnancy with the fetus being compromised by remaining within an infected environment. Also, rare cases of erythromycin causing adverse effects in newborn infants, including cardiovascular compromise and hypertrophic pyloric stenosis, have been reported [47] . Because erythromycin is a broad-spectrum antibiotic, the potential also exists to target beneficial microbes, such as the normal gut flora of the neonate, which is crucial in development of the naive immune system of newborn babies [48] . Finally, there remains the issue of increasing antimicrobial-resistant microorganisms because of the unnecessary overuse of antibiotics. Recently, Krausse and Schubert [49] investigated the susceptibilities of clinical ureaplasma isolates collected from 1983 and from 1989 to 2008 to various antimicrobials. Those authors found that ureaplasmas showed reduced susceptibilities to all classes of antimicrobials tested throughout the time period, and high levels of erythromycin resistance were observed from isolates collected during the period from 1989 to 2008.
The results of the present study provide further evidence that the use of erythromycin in pregnancy is ineffective because of its limited ability to cross the placenta. Further research is urgently required to explore alternative antimicrobial treatments for women at risk of preterm birth.
